INSILICO (03696) announced that, based on the results of the Hang Seng Indexes Company's quarterly index review for Q1 2026, the company will be included as a constituent of the Hang Seng Biotechnology Index. The inclusion will be implemented after market close on Friday, June 5, 2026, and will take effect from Monday, June 8, 2026. The Hang Seng Biotechnology Index aims to reflect the overall performance of the 30 largest biotechnology companies listed in Hong Kong that are also eligible for the Hong Kong Stock Connect program. The board believes that this inclusion into the Hang Seng Biotechnology Index constituents fully demonstrates the capital market's recognition and confidence in the company's long-term development potential. Concurrently, the company's shares are expected to be incorporated into a broader range of index funds and core portfolios of institutional investors, further expanding the investor base, enhancing trading liquidity, and strengthening risk resilience. The board expressed gratitude to the company's shareholders and investors for their ongoing support.